All Neurosciences articles – Page 2
-
NewsTargeting cPLA2 enzyme may reduce brain inflammation in Alzheimer’s
Researchers have identified new drug candidates that selectively target the cPLA2 enzyme, a key driver of brain inflammation linked to Alzheimer’s disease, offering a potential new approach to reducing risk in people with the APOE4 gene.
-
NewsHIV drug Maraviroc could be used to slow glioblastoma growth
Researchers have discovered how seemingly supportive brain cells help glioblastoma thrive, whilst identifying an existing HIV drug, Maraviroc, that could be repurposed to slow tumour growth.
-
NewsHow ageing cells affect brain development and neurodegeneration
New research has revealed how cellular senescence – the process in which ageing cells change function – shapes human brain structure from development to old age, improving our understanding of brain ageing and neurodegenerative diseases.
-
ArticleRethinking drug discovery through transcription factor biology
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
-
NewsNew study revives long-doubted target for depression drugs
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
-
NewsRare sugars point to future therapies for alcohol dependence
Researchers have identified a biological pathway linking sugar and appetite for alcohol, suggesting that rare sugars could one day form the basis of new therapies and approaches for reducing alcohol consumption and treating dependence.
-
NewsOTULIN enzyme found to drive tau and brain ageing
Researchers have discovered that the enzyme OTULIN, known for regulating the immune system, also drives the formation of tau – a protein linked to Alzheimer’s and other neurodegenerative diseases.
-
ArticleWhy tau still lacks treatments and how funders are responding
Tau drives PSP, CBD and other neurodegenerative diseases, yet there are still no disease-modifying treatments. Here, Dr Glenn Harris from the Rainwater Charitable Foundation shares how a coordinated funding effort is supporting basic research to understand tau mechanisms, improve detection and progress therapeutic development.
-
NewsMaternal stress may alter foetal brain development via immune pathways
Stress during pregnancy may disrupt the maternal gut-immune system, altering foetal brain development and revealing sex-specific vulnerabilities linked to neurodevelopmental risk
-
NewsNew Lumos AI platform targets precision in mental health drugs
Headlamp Health has launched Lumos AI®, a new decision-support platform designed to bring greater precision to neuroscience drug development.
-
NewsPropofol and insulin may reduce cognitive decline in older age
New research from the University of Illinois suggests that widely used drugs, including propofol and intranasal insulin, could help protect ageing brains from memory decline and postoperative cognitive impairment.
-
NewsBrain ‘master switch’ discovery could lead to new neurodegenerative therapies
Scientists have captured, for the first time, dynamic changes in a crucial neuronal ‘master switch’ inside the living brain, potentially informing new future treatments for neurodegenerative diseases.
-
NewsHomer1 gene discovery could lead to new ADHD therapies
A new study published has demonstrated that reducing background brain activity can sharpen attention, identifying the Homer1 gene as key to developing new targeted treatments for ADHD and related disorders.
-
NewsNew research aims to make FDA-approved drugs safer for the brain
Life-saving HIV and cancer drugs can carry serious neurological risks, and new funding will help UMBC researchers discover how these medicines damage the brain – which could help to inform safer treatments.
-
NewsExperimental drug NU-9 reduces toxic amyloid in early Alzheimer’s
A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.
-
NewsParkinson’s: new study rethinks dopamine’s role in movement
A new study is challenging long-held beliefs about dopamine’s role in movement, revealing new insights into how Parkinson’s disease treatments work and pointing towards more targeted future therapies.
-
NewsBrain drainage repair offers potential new prevention therapies for Alzheimer’s
UVA researchers have discovered a potential treatment approach that restores the brain’s natural drainage system, offering hope for preventing traumatic brain injury-related neurodegeneration.
-
NewsPlatelet-inspired nanoparticles could improve treatment of inflammatory diseases
Scientists have developed platelet-inspired nanoparticles that deliver anti-inflammatory drugs directly to brain-computer interface implants, doubling their effectiveness.
-
NewsResearchers identify new drug site on epilepsy target SV2A
A team led by St. Jude Children’s Research Hospital and UT Southwestern has mapped how key anti-epilepsy drugs latch onto their neural target, SV2A.
-
NewsOTULIN enzyme found to control tau production in Alzheimer’s
New research has shown that the enzyme OTULIN regulates tau at the gene-expression level rather than through protein degradation.